PharmAust Limited (ASX:PAA) is a public company listed on the Australian Securities Exchange. The principal activities of the company are to develop its own drug discovery intellectual property, namely three platforms for the treatment of different types of cancers in humans and animals, as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients.
Pitney Pharmaceuticals Pty Ltd is an Australian company, which is in the business of developing therapeutic cancer products. It has exclusive rights to three oncology technology platforms, which are being developed with an aim to improve the outcomes of patients with inoperable and often terminal cancers. Pitney is a 100% wholly owned subsidiary of PharmAust Limited.
Epichem is an Australian company formed in 2003 to provide services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. With two state-of-the-art laboratories in Perth and Melbourne, Epichem serves an international clientele ranging from small operations to large multinational pharmaceutical companies.
Dave Gentry, host of "The RedChip Money Report", interviews Dr. Roger Aston, Executive Chairman of PharmAust Ltd (ASX: PAA) as aired on Bloomberg TV.
©2013 PharmAust Limited (ABN 35 094 006 023)
Tel: +61 8 6364 0899 | Fax: +61 8 9467 6111
Pharmaust © 2013 | All Rights Reserved Online Marketing & Website Design By Total Click Solutions